ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

GANX Gain Therapeutics Inc

2.96
0.00 (0.00%)
Pre Mercado
Última actualización: 06:00:00
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Gain Therapeutics Inc GANX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.00% 2.96 06:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.96
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
24/4/202408:25GLOBEGain Therapeutics Announces Positive Results from the Single..
08/4/202408:25GLOBEGain Therapeutics Bolsters Management Team with the..
01/4/202408:25GLOBEGain Therapeutics Strengthens Management Team and Appoints..
26/3/202407:00GLOBEGain Therapeutics Reports Financial Results for Year End..
15/3/202413:30GLOBEGain Therapeutics to Present at Public Ventures Discovery..
05/3/202407:00GLOBEGain Therapeutics Presents Data at the AD/PD™ 2024..
27/2/202413:00GLOBEGain Therapeutics Announces the Initiation of the Multiple..
22/2/202406:00EDGAR2Form 8-K - Current report
14/2/202411:29GLOBEGain Therapeutics Announces 2024 R&D Update on Parkinson’s..
06/2/202408:56GLOBEUPDATE - Gain Therapeutics’ GT-02287 Completely Restores..
06/2/202407:00GLOBEGain Therapeutics’ GT-02287 Completely Restores Motor..
31/1/202416:26EDGAR2Form 8-K - Current report
31/1/202407:00GLOBEGain Therapeutics’ CEO Matthias Alder Issues Letter to..
02/1/202415:09EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
02/1/202407:00GLOBEGain Therapeutics Announces Acceptance of Late-Breaking..
01/1/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
19/12/202315:52EDGAR2Form S-1 - General form for registration of securities under..
01/12/202307:00GLOBEGain Therapeutics Announces Preclinical Data Showing..
29/11/202307:00GLOBEGain Therapeutics to Participate in AI Driven Drug Discovery..
24/11/202312:01GLOBEGain Therapeutics Announces Closing of $10.1 Million Public..
24/11/202305:07EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
22/11/202316:27EDGAR2Form 8-K - Current report
21/11/202307:54GLOBEGain Therapeutics Announces Pricing of $9.4 Million Public..
20/11/202315:22EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20/11/202315:03GLOBEGain Therapeutics Announces Proposed Public Offering
17/11/202315:27EDGAR2Form 8-K - Current report
14/11/202315:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/11/202315:02EDGAR2Form 8-K - Current report
14/11/202306:00GLOBEGain Therapeutics Announces Third Quarter 2023 Financial..
04/10/202306:00GLOBEGain Therapeutics Announces Dosing of First Two Subjects in..
25/9/202315:05GLOBEGain Therapeutics to Participate at Cantor Fitzgerald Global..
20/9/202315:05GLOBEGain Therapeutics to Present at the Cambridge Healthtech..
12/9/202308:25GLOBEGain Therapeutics Receives Approval to Commence Phase 1..
10/8/202315:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202315:02EDGAR2Form 8-K - Current report
10/8/202306:00GLOBEGain Therapeutics Announces Second Quarter 2023 Financial..
07/8/202306:00GLOBEGain Therapeutics Announces Acceptance of Late Breaking..
31/7/202307:00GLOBEGain Therapeutics to Participate in the 2023 BTIG Virtual..
01/6/202307:00GLOBEGain Therapeutics to Present at the Jefferies Healthcare..
12/5/202307:00GLOBEGain Therapeutics Reports First Quarter 2023 Financial..

Su Consulta Reciente

Delayed Upgrade Clock